Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MITF | O75030 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | GMNN | O75496 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kinetin Riboside SCHEMBL17825970 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL29564117 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL3339041 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL3190252 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL14713232 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL3190271 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL19583061 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL14713468 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| SCHEMBL25170466 | 0.99 | ADORA3 (0.98) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| SCHEMBL29697393 | 0.99 | ADORA3 (0.98) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014184-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2026-01-15 | — | — | US | claimed |
| EP-4633645-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | University College Cardiff Consultants Limited (GB) | 2025-10-22 | — | — | EP | claimed |
| US-20240207302-A1 | ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF | CALIXTO JOAO BATISTA (BR) | 2024-06-27 | — | — | US | claimed |
| WO-2024126991-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2024-06-20 | — | — | WO | claimed |
| WO-2024029755-A1 | ANIMAL MODEL OF CHARCOT-MARIE-TOOTH DISEASE | 동아대학교 산학협력단 | 2024-02-08 | — | — | WO | claimed |
| EP-4314001-A1 | ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF | Calixto, João Batista (BR) | 2024-02-07 | — | — | EP | claimed |
| US-20220389067-A1 | Methods of Treating Neurodegenerative Diseases Caused by G4C2 Expansion in C9ORF72 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-08 | — | — | US | claimed |
| WO-2022204770-A1 | ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF | NALLAR JAIME ALBERTO RABI (BR) | 2022-10-06 | — | — | WO | claimed |
| WO-2022204777-A1 | ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF | CALIXTO JOAO BATISTA (BR) | 2022-10-06 | — | — | WO | claimed |
| EP-3500271-A1 | GENOME EDITING ENHANCERS | Bluebird Bio, Inc. (US) | 2019-06-26 | — | — | EP | claimed |
| US-20100144685-A1 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2010-06-10 | — | — | US | claimed |
| WO-2010025297-A2 | HYBRID PEPPER PLANTS RESULTING FROM A CROSS BETWEEN C. ANNUUM AND C. PUBESCENS | SEMINIS VEGETABLE SEEDS, INC. (US) | 2010-03-04 | — | — | WO | claimed |
| US-20090214710-A1 | Methods and Compositions For Increasing Fermentation of a Microorganism | VDF FUTURECEUTICALS, INC. (US) | 2009-08-27 | — | — | US | claimed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| WO-2008045955-A9 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION (US) | 2008-10-02 | — | — | WO | claimed |
| WO-2008045955-A2 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-04-17 | — | — | WO | claimed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | claimed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050042327-A1 | Methods and compositions for increasing fermentation of a microorganism | VDF FUTURECEUTICALS | 2005-02-24 | — | — | US | claimed |
| US-6168952-B1 | REGENERATING PLANTS FROM RHIZOME IN MEDIUM, ROOT EXCISION, CULTURING IN MEDIUM CONTAINING LOW NITROGEN AND ENHANCED PHOSPHOROUS CONTENT AND 6-BENZYLADENINE | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2001-01-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014184-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ADRM1, ADORA1, ADORA2A | ADORA3 8/4885SLC29A1 284/4885TP53 61/4885 |
| US-20240207302-A1 | ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF | RNGTT, ACE2, ACE | ADORA3 121/4885SLC29A1 152/4885TP53 1010/4885 |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | ADORA3 162/4885SLC29A1 710/4885TP53 2033/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | ADORA3 153/4885SLC29A1 670/4885TP53 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.